Periodontal disease and systemic amyloidosis: From inflammation to amyloidosis — a troubling connection

Cengiz et al. Vol.10 No.1

It has become increasingly clear in recent years that periodontal disease can cause dramatic increases in the levels of markers of systemic inflammation and can also result in reductions in the levels of these markers. It is also known that amyloid fibril deposits derived from circulating acute-phase reactant serum amyloid A (SAA) lead to systemic AA amyloidosis. However, in up to approximately 12% of cases of AA amyloidosis no underlying etiology can be identified. Periodontal evaluations are not normally performed as a part of the medical assessment of patients with AA amyloidosis. Hence, destructive periodontal diseases may be an overlooked source of inflammation in these patients. Periodontal diseases have not been investigated in systemic AA amyloidosis with unknown etiology. Our hypothesis is that periodontitis may be an important occult source of chronic inflammation that increases the levels of acute-phase reactants, which, in turn, might affect or cause the development of systemic AA amyloidosis.

Periodontal diseases are moving into the focus of systemic diseases. Periodontitis is a chronic and occult infection. Our hypothesis is that periodontitis should be considered as a possible etiological factor along with the traditional factors for systemic AA amyloidosis.

Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders (1, 2). It has been demonstrated biochemically that AA amyloidosis results from abnormal accumulation of proteins, which are deposited as insoluble fibrils in extracellular tissue, leading to the disruption of their normal function (1). Although recent decades have provided significant advances in our understanding of the pathology and pathogenesis of AA amyloidosis, the mechanism and physiological factors promoting AA amyloidosis are largely unknown (1). Its pathogenesis is multifactorial, involving many variables such as the primary structure of the precursor protein, the acute-phase response, the presence of non-fibril proteins, receptors, lipid metabolism and proteases (2).

The modern classification of amyloidosis is based on the nature of the precursor plasma proteins that form the fibril deposits and is divided into two types: primary amyloidosis and secondary amyloidosis (3). Secondary amyloidosis is caused by amyloid derived from serum amyloid A, an acute-phase protein produced in response to inflammation (1-4). Approximately 45% of cases of systemic amyloidosis are secondary or reactive (AA) amyloidosis. Among the causes of AA amyloidosis are various chronic inflammatory conditions such as rheumatoid arthritis, sarcoidosis, Crohn’s disease, ulcerative colitis, tuberculosis, idiopathic diseases and inherited diseases like familial Mediterranean fever (FMF) (1-4). AA amyloidosis is also associated with malignant diseases such as Hodgkin’s disease and mesothelioma (2). The absolute and relative prevalences of the individual diseases associated with AA amyloidosis show significant geographical and temporal differences. With the decline of tuberculosis in the West, chronic rheumatic and idiopathic inflammatory diseases have become the leading causes of AA amyloidosis (2). However, in the Third World and on the Indian subcontinent, chronic infectious diseases such as tuberculosis and leprosy remain the major causes (2). In approximately 6 to 12% of cases of AA amyloidosis, no underlying disease can be found (4,5).

It has long been known that AA amyloidosis occurs after a lengthy period of ongoing inflammatory and/or infectious disease. Therefore, AA amyloidosis may not be suspected during the early course of a potential chronic or recurrent inflammatory disease. However, in rare cases it may occur within a year of a clinically apparent inflammatory disease (6,7). AA amyloidosis does not occur in the absence of an acute-phase response or without elevated SAA levels. Synthesis and secretion of acute-phase SAA is mediated by cytokines, mainly interleukin-1 (IL-1), IL-6, IL-10 and tumour necrosis factor-alpha (TNF-alpha) (1-10). The SAA proteins are multifunctional apolipoproteins that are involved in cholesterol transport and metabolism, and in modulating numerous immunological responses during inflammation and the acute-phase response to infection, trauma or stress. During the acute-phase response, the hepatic biosynthesis of SAA is up-regulated by pro-inflammatory cytokines, and circulating concentrations can increase by up to 1000-fold. Chronically elevated SAA concentrations are a prerequisite for the pathogenesis of AA amyloidosis (11).

Renal dysfunction is the predominant disease manifestation of AA amyloidosis. It has been reported that mortality, amyloid burden and renal prognosis are all significantly correlated with SAA. The synthesis of SAA is largely regulated by inflammation-associated cytokines, peptide hormone signals produced by endothelial cells, lymphocytes and, in particular, activated monocytes and macrophages (12). The activation pattern and prognostic value of the SAA protein in inflammation is similar to that of C-reactive protein (CRP) (13,14). The progressive nature of AA amyloidosis largely reflects the persistent nature of the underlying conditions and, due to fluctuations of disease activity, not all patients show evidence of an acute-phase response at the time of diagnosis (2).

Periodontal disease shares several clinical and etiopathogenic characteristics with AA amyloidosis. Cross-sectional studies have demonstrated that plasma levels of inflammatory markers such as CRP, fibrinogen, IL-1, IL-6 and leukocyte counts increase in patients with periodontitis when compared with periodontally healthy patients (15). Studies reported decreases in both IL-6 and CRP 6 months after initial periodontal therapy alone (16,17). Taken together, these studies suggest that not only can periodontitis elevate acute-phase reactants of inflammation, but also that effective periodondal therapy may decrease the acute-phase response.

The above reports are of significance for patients with AA amyloidosis because elevation in serum inflammatory markers such as CRP, IL-1, IL-6 and TNF-alpha has been reported to be a robust predictor of AA amyloidosis. It is also known that chronic infection or inflammatory disease may cause AA amyloidosis, even without obvious infection or inflammation (18,19). In addition to the fact that localized deposits of amyloid in patients with systemic AA amyloidosis can aggrevate periodontal disease, chronic periodontal diseases may exaggerate AA amyloidosis via increased levels of systemic inflammatory mediators. Indeed, patients with chronic periodontal diseases have higher levels of SAA — the precursor protein of amyloid fiber in AA amyloidosis — than patients without periodontal disease (20). Therefore, elimination of the local infection associated with periodontal diseases will aid in reducing levels of systemic inflammatory mediators, which may slow the progression of AA amyloidosis (21).

Periodontal infections are polymicrobial and result from the accumulation of bacterial plaque and dental calculus at the gingival margin (22). These infections develop over several years and are often asymptomatic and painless, but may eventually lead to loss of teeth. Periodontal infections are widely regarded as one of the most common diseases worldwide, with a prevalence of 10% to 15% (22). A recent health examination survey from Finland involving 6300 participants revealed that up to 64% of the adult population had deepened gingival pockets associated with periodontitis, and nearly 20% had a severe form of this disease with pocket deeper than 6 mm (23).

Periodontitis may be linked to a secondary disease by three pathways: infection due to transient bacteremia; immunological response; and toxic injury. This fits well with the modern concept of focal infection (24). One cubic millimeter of dental plaque contains about 100 milion bacteria and may serve as a persistent reservior for potential pathogenic bacteria (24). Subgingivally located bacteria, and bacterial components and products, especially endotoxins, may easily enter the blood circulatory system via the infected and injured epithelium of deepened gingival pockets, as well as after daily oral hygiene routines. Even gentle mastication leads to increased release of bacterial endotoxins into the peripheral blood (25). Such bacterial release, as well as systemic inflammation induced by local inflammation mediators, very likely occurs in patients with periodontitis, not just transiently but also long-term. Continuous exposure to several periodontal pathogens fits with the theory of the role of infections in amyloidosis. Total pathogen burden (the number of pathogens) and endotoxemia (the concentration and activity of endotoxins) to which an individual has been exposed may contribute to AA amyloidosis. The systemic immune response, genetic factors and environmental factors also affect the risk of developing periodontitis (26).

Although periodontitis and AA amyloidosis have many features in common, to our knowledge the only reports on the subject are the three reports that we have published (27-29).

One of our studies (27) was a case report that documented secondary amyloidosis, which was supported by the tongue, buccal mucosa and retromolar trigon and renal biopsies, while ruling out known possible etiologic factors as the cause of the secondary amyloidosis. Our patient developed AA amyloidosis, most likely secondary to his long-standing periodontitis. Moreover, this study demonstrated that secondary amyloidosis can be slowed down if periodontal conditions can be improved.

Our second study (28) showed that the prevalence of moderate to severe periodontitis in patients with FMF with amyloidosis (80.6%) was significantly greater than those in patients with FMF without amyloidosis (38%) and control patients (20%). In addition, serum levels of acute-phase reactants in patients with FMF were reduced significantly following nonsurgical periodontal therapy.

Our third study (29), which analyzed the etiological distribution of 112 patients with systemic AA amyloidosis, showed that FMF (52.7%) and chronic inflammatory and neoplastic diseases (35.7%) were the leading causes of systemic AA amyloidosis, while periodontal disease was found in 11.6% of the patients in the study. The prevalence of moderate to severe periodontitis was 47.5% in patients with FMF, 72.5% in patients with known chronic inflammatory diseases and 84.7% in patients with periodontal disease. Serum levels of acute-phase reactants in patients with AA amyloidosis were reduced significantly following nonsurgical periodontal therapy. We suggested that periodontitis may be an important occult source of chronic inflammation that increases the levels of the acute-phase reactants in these patients and hence might affect the development of AA amyloidosis.

The major determinants of individual susceptibility to chronic periodontitis are the host responses to pathogens. Recent data suggest that bacteria and bacterial products present in dental plaque and crevicular fluid can stimulate immune cells to produce and release numerous inflammatory mediators, such as TNF-alpha, IL-1, IL-6, IL-10 and interferons (30). In patients with chronic periodontitis, the total amount of IL-6 and TNF-alpha in gingival crevicular fluid is increased (31,32). The genetic cause of AA amyloidosis in patients with FMF is not completely understood. It appears to be associated with MEFV gene M694V homozygosity and differences in serum amyloid A (33-36). However, there are also reports that do not confirm this association (37,38). Furthermore, genetic variants of some cytokines confer susceptibility to periodontitis (39). In addition, in aggressive periodontitis, genetically determined host responses and microbiological factors appear to be deterministic components, which may trigger or cause the onset of these diseases (40). These findings support the hypothesis suggesting that complex interactions between the microbiota and the host genome may be the basis of susceptibility to aggressive periodontitis (39). The systemic immune response, and genetic and environmental factors also affect the risk of developing periodontitis and amyloidosis (2,26).

Periodontitis is such a powerful background infection that it reduces, and even hinders, the antimicrobial efficacy of antibiotics in preventing systemic events. Due to its biofilm nature, mechanical treatment of the disease is necessary for the treatment of periodontal disease because it is resistant to systemic antibiotics alone.

We believe that periodontitis may be an additive factor to traditional etiological factors for systemic AA amyloidosis as well as being a primary etiological factor. Therefore, treating or preventing periodontitis may help alleviate disease burden or may even prevent the development of systemic AA amyloidosis. Based on this, we suggest that periodontal evaluation should be performed as a part of the medical assessment of patients with systemic AA amyloidosis.

Murat Inanç Cengiz graduated from Ondokuz Mayıs University Faculty of Dentistry in 2002. He received his PhD from Ondokuz Mayıs University, School of Dentistry, Department of Periodontology. After his PhD, he worked in Vezirköprü Oral Health Center as a general practioner between 2008 – 2009. He has been working in Zonguldak Karaelmas University, School of Dentistry, Department of Periodontology as an Assistant Professor and he is the director of the department. His area of interests are Periodontal Surgery, interaction between systemic diseases and Periodontal Diseases, and Periodontal Medicine.


1 Elimova E, Kisilevsky R, Ancsin JB. Heparan sulfate promotes the aggregation of HDL associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J. 2009; 23:3436-48. PMid:19549924

2 Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002; 440:111-12.

3 Khan MF, Falk RH. Amyloidosis. Postgrad Med J. 2001; 77:686-93. PMid:11677276 PMCid:1742163

4 Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356:2361-71. PMid:17554117

5 Paydas S. Report on 59 patients with renal amyloidosis. Int Urol Nephrol. 1999; 34:619-31. PMid:10755352

6 Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000; 93: 535-42. PMid:10924536

7 Röcken C, Radun D, Glasbrenner B, Malfertheiner P, Roessner A. Generalized AA-amyloidosis in a 58-year-old Caucasian woman with an 18-month history of gastrointestinal tuberculosis. Virchows Arch. 1999; 434:95-100.

8 Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358:24-9.

9 Husby G, Marhaug G, Dowtor B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid. 1994; 1:119-37.

10 Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993; 102:131-46.

11 Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J. 1998; 334:489-503.
PMid:9729453 PMCid:1219714

12 Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990; 4:2860-7.

13 Yalçınkaya F, Çakar N, Acar B, Tutar E, Güriz H, Elhan AH, et al. The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. Rheumatol Int. 2007; 27:517-22. PMid:17103173

14 Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of c-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994; 331:417-24. PMid:7880233

15 Craig RG, Yip JK, So MK, Boylan RJ, Socransky SS, Haffajee AD. Relationship of destructive periodontal disease to the acute-phase response. J Periodontol. 2003; 74:1007-16. PMid:12931763

16 D’Aiuto F, Parkar M, Andreou G, Suvan J, Brett PM, Ready D, et al. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res. 2004; 83:156-60. PMid:14742655

17 D’Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res. 2005; 84:269-73. PMid:15723869

18 Cengiz K. Uncommon aetiology in renal amyloidosis. Acta Clin Belg. 2005; 60:109-13.

19 Nasr SH, Schwarz R, D’Agati VD, Markowitz GS. Paraplegia, proteinuria, and renal failure Kidney Int. 2006; 69:412-5. PMid:16408135

20 Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, et al. Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol. 2002; 9:425-32.
PMid:11874889 or PMCid:119918

21 Khoury S, Dusek JJ, Anderson GB, Vigneswaran N. Systemic amyloidosis manifesting as localized, severe periodontitis. J Am Dent Assoc. 2004; 135:617-23.

22 Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 366: 1809-20.

23 Knuuttila M. Hampaiden kiinnityskudossairau-det [periodontal diseases] in Suominen —Taipale L, Nordblad A, Vehkalahti M, Aromaa A, editors. Suomalaisten aikuisten suunterveys [Oral health in the Finnish adult population]. Terveys 2000 -tutkimus [Health 2000survey]. Helsinki: Publication of the National Public Health Institute; 2004. p 88-97.

24 Thoden van Velzen SK, Abraham-Inpijn L, Moorer WR. Plaque and systemic disease: a reappraisal of the focal infection concept. J Clin Periodontol. 1984; 11:209-20. PMid:6368612

25 Geerts SO, Nys M, De MP, Charpentier J, Albert A, Legrand V, et al. Systemic release of endotoxins induced by gentle mastication: association with periodontitis severity. J Periodontol. 2002; 73:73-8. PMid:11846202

26 Agrawal AA, Kapley A, Yeltiwar RK, Purohit HJ. Assessment of single nucleotide polymorphism at IL-1A+4845 and IL-1B+3954 as genetic susceptibility test for chronic periodontitis in Maharashtrian ethnicity. J Periodontol. 2006; 77:1515-21. PMid:16945028

27 Cengiz MI, Wang HL, Yıldız L. Oral involvement in a case of AA amyloidosis: a case report. J Med Case Reports. 2010; 4:200-6. PMid:20591157 PMCid:2911467

28 Cengiz MI, Ba˘gcı H, Cengiz S, Yi˘git S, Cengiz K. Periodontal disease in patients with familial Mediterranean fever: from inflammation to amyloidosis. J Periodontol Res. 2008; 44:354-61. PMid:18973533

29 Cengiz MI, Yayla N, Cengiz K, Ba ˘gcı H, Taskın E. Interaction between periodontal disease and systemic secondary amyloidosis: from inflammation to amyloidosis. J. Periodontol. 2011; 82:566-74. PMid:21043797

30 Bodet C, Chandad F, Grenier D. Porphyromonas gingivalis-induced inflammatory mediator profile in an ex vivo human whole blood model. Clin Exp Immunol. 2006; 143:50-7. PMid:16367933 PMCid:1809557

31 Lin SJ, Chen YL, Kuo MY, Li CL, Lu HK. Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. Cytokine. 2005; 30: 160-7. PMid:15863389

32 Kurti¸s B, Tüter G, Serdar M, Akdemir P, Uygur C, Firatli E, et al. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. J Periodontol. 2005; 76:1849-55. PMid:16274303

33 Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008; 18:109-18. PMid:18369528

34 Yi ˘git S, Ba˘gci H, Ozkaya O, Ozdamar K, Cengiz K, Akpolat T. MEFV mutations in patients with familial Mediterranean fever in the Black Sea region of Turkey: Samsun experience. J Rheumatol. 2008; 35:106-13.

35 Cazeneuve C, Sarkisan T, Pêcheux C, Dervichian M, Nédelec B, Reinert P, et al. MEVF-Gene analysis in Armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet. 1999; 65:88-97. PMid:10364520

36 Ben-Chetrit E. Familial Mediterranen fever (FMF) and renal AA amyloidosis-phenotype-genotype correlation, treatment and prognosis. J Nephrol. 2003; 16:431-4.

37 El-Shanti H, Majeed AH, El-Khateeb M. Familial Mediteranean fever in Arabs. Lancet. 2006; 367:1016-24.

38 Yalçinkaya F, Cakar N, Misirlio˘glu M, Tümer N, Akar N, Tekin M, et al. Genotype-phenotype correlation in large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis Rheumatology. 2000; 67-72.

39 Nibali L, Donos N, Brett PM, Parkar M, Ellinas T, Llorente M, et al. A familial analysis of aggressive periodontitis – clinical and genetic findings. J Periodontol Res. 2008; 43:627-34. PMid:18752567

40 Tonetti MS, Claffey N, European Workshop in Periodontology group C. Advances in the progression of periodontitis and proposal of definitions of a periodontitis case and disease progression for use in risk factor research. Group C consensus reporth of the 5th European Workshop in Periodontology. J Clin Periodontol. 2005; 32(Suppl 6):210-3. PMid:16128839

Share your thoughts

Leave a Reply

You must be logged in to post a comment.